Penumbra Trails Coloplast with Forward P/E of 67.0 and PEG of 2.09
Penumbra holds a Zacks Rank of #4 (Sell) and a Style Score Value grade of D, trailing Coloplast’s Zacks Rank #2 and Value grade B. Penumbra’s forward P/E is 67.01, PEG ratio 2.09 and P/B ratio 9.78 versus Coloplast’s 19.03, 0.75 and 7.91 respectively.
1. Zacks Rank and Style Score Comparison
Penumbra has a Zacks Rank of #4 (Sell) based on earnings estimate revisions, while Coloplast holds a Zacks Rank of #2 (Buy). The Style Score system incorporates fundamental traits to assign a Value grade of D to Penumbra and B to Coloplast, indicating relative undervaluation of Coloplast.
2. Forward P/E, PEG and P/B Ratio Analysis
Penumbra’s forward P/E ratio stands at 67.01, PEG ratio at 2.09 and P/B ratio at 9.78, reflecting premium valuation relative to book value and growth expectations. Coloplast sports a forward P/E of 19.03, PEG of 0.75 and P/B of 7.91, signaling more attractive valuation metrics for value investors.
3. Value Grade Outcomes and Investor Implications
Coloplast’s stronger estimate revisions and more favorable fundamental ratios underpin its Style Score Value grade of B versus Penumbra’s D. Value investors prioritizing low P/E, PEG and solid cash flow metrics are likely to favor Coloplast over Penumbra based on current data.